Effect of clopidogrel on YKL-40 and NF-κB levels in patients undergoing percutaneous coronary intervention with coronary heart disease with diabetes mellitus / 药物评价研究

ABSTRACT

Objective To explore the effect of clopidogrel on the YKL-40 and NF-κB levels in patients undergoing percutaneous coronary intervention with coronary heart disease with diabetes mellitus.Methods Totally 80 patients undergoing percutaneous coronary intervention with coronary heart disease with diabetes mellitus were collected in our hospital from August 2013 to December 2016,and divided into two groups randomly,control group (n =40) were adopted aspirin treatment during perioperative period,study group (n =40) were adopted clopidogrel based on the treatment of control group.The platelet aggregation of two groups were compared after treatment,and the curative effect was evaluated and analyzed;The level of chitinase-3 like protein-1 (YKL-40) and nuclear factor κB (NF-κB) were detected before and after treatment;The adverse reactions of patients in two groups during perioperative period were recorded and analyzed.Results After 7 d treatment,the platelet aggregation rate of study group were significantly lower than those patients in control group (P ＜ 0.05).The total effective rate of study group was significantly higher than that of control group (P ＜ 0.05).After treatment,the YKL-40 and NF-κB levels of all patients decreased significantly compared with pre-treatment (P ＜ 0.05),and the content was lower than that in control group (P ＜ 0.05);The difference of thrombocytopenia and gastrointestinal bleeding incidence between two groups has no significance.Although the incidences of myocardial infarction,angina pectoris and death were lower than those in control group,the difference between two groups has no significance.The total incidence of adverse reactions of patients in study group was lower significantly than that in control group (P ＜ 0.05).Conclusion Clopidogrel combined with aspirin for antiplatelet therapy in patients undergoing percutaneous coronary intervention with coronary heart disease with diabetes mellitus deserves popularization in clinical,which not only possesses well clinical curative effect and safety,but controls the inflammatory response and decreases adverse reactions.